To investigate whether interfering with REG4 expression would affect tumor ability to evade immune system, we inactivated REG4 gene in type I MSS CRC immunotherapy-resistant PDO model with high REG4 expression (Supplementary Fig. S5A) using small guide RNA (sgRNA) pairs designed to delete the transcription start site. This evidence concerns the gene REG4 and colorectal carcinoma.